Fig. 8: Gankyrin knockdown inhibits EMT and tumor progression in vivo. | Cell Death Discovery

Fig. 8: Gankyrin knockdown inhibits EMT and tumor progression in vivo.

From: Gankyrin modulated non-small cell lung cancer progression via glycolysis metabolism in a YAP1-dependent manner

Fig. 8

A Macroscopic observation of the size of tumor nodules in nude mice bearing xenograft tumors with A549-sh-Gankyrin or sh-NC. B Statistical analysis of tumor weight in different groups (n = 6, **P < 0.01). C Statistical analysis of tumor growth curves in different group (n = 6, *P < 0.05). D Immunohistochemistry assay was applied to determine the expression of E-cadherin, Vimentin, YAP1, and Gankyrin in a cell-derived xenograft tumor model (Scale bars: 100 μm). E, F Expression of Gankyrin, and YAP1, and EMT-relevant markers, including E-cadherin, N-cadherin, and Vimentin in different groups, as determined by using qRT-PCR (n = 6, *P < 0.05, **P < 0.01). G Western blotting assay results show the protein levels of the EMT-relevant markers E-cadherin, ZO-1, FN1, N-cadherin, and Vimentin (n = 6, *P < 0.05, **P < 0.01).

Back to article page